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Abstract 
Background: The importance of platelets in the pathogenesis of metastasis formation is increasingly recognized. 
Although evidence from epidemiologic studies suggests positive effects of aspirin on metastasis formation, there is 
little clinical data on the perioperative use of this drug in pancreatic cancer patients.
Methods: From all patients who received curative intent surgery for pancreatic cancer between 2014 and 2016 at 
our institution, we identified 18 patients that took aspirin at time of admission and continued to throughout the inpa-
tient period. Using propensity score matching, we selected a control group of 64 patients without aspirin intake from 
our database and assessed the effect of aspirin medication on overall, disease-free, and hematogenous metastasis-
free survival intervals as endpoints.
Results: Aspirin intake proved to be independently associated with improved mean overall survival (OS) (46.5 vs. 
24.6 months, *p = 0.006), median disease-free survival (DFS) (26 vs. 10.5 months, *p = 0.001) and mean hematogenous 
metastasis-free survival (HMFS) (41.9 vs. 16.3 months, *p = 0.005). Three-year survival rates were 61.1% in patients with 
aspirin intake vs. 26.3% in patients without aspirin intake. Multivariate cox regression showed significant independent 
association of aspirin with all three survival endpoints with hazard ratios of 0.36 (95% CI 0.15–0.86) for OS (*p = 0.021), 
0.32 (95% CI 0.16–0.63) for DFS (**p = 0.001), and 0.36 (95% CI 0.16–0.77) for HMFS (*p = 0.009).
Conclusions: Patients in our retrospective, propensity-score matched study showed significantly better overall sur-
vival when taking aspirin while undergoing curative surgery for pancreatic cancer. This was mainly due to a prolonged 
metastasis-free interval following surgery.
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Background
In early stages of pancreatic cancer, surgical resection is 
the most important pillar of therapy. However, a signifi-
cant proportion of patients will subsequently develop and 
succumb to distant metastases due to clinically undetect-
able micrometastasis at the time of surgery.
The “invasion-metastasis cascade” that a localized pri-
mary tumor undergoes in order to form metastases, is 
highly dependent on interactions with healthy cells and 
components from the surrounding tumor microenvi-
ronment [1]. It is highly inefficient concerning the very 
small proportion of circulating tumor cells (CTCs) that 
will successfully form overt metastases in distant organs. 
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The vast majority of CTCs dies from sheer stress or 
elimination by immune cells [2, 3]. Platelets within the 
circulation collaborate closely with CTCs, protect them 
from natural killer cells, sustain epithelial–mesenchymal 
transition (EMT) signals and promote survival through 
paracrine signals [4]. Thrombocytosis is frequently asso-
ciated with poor survival and inhibition of platelets can 
diminish metastasis formation [5, 6]. Thus, the impor-
tance of platelets in facilitating metastasis is undisputed 
[7].
Aspirin, which is a potent inhibitor of platelet function-
ality, has been shown to positively affect cancer incidence 
and cancer-related mortality as reported in epidemiologi-
cal studies and meta-analysis of randomized controlled 
trials for cardiovascular prevention [8–11]. However, 
only recently randomized controlled trials assessing the 
effect of aspirin on cancer survival were initiated [12, 13], 
none of which assess the effect of aspirin in the setting of 
pancreatic cancer surgery.
Despite the overall positive effect that resection of the 
primary tumor has on the patient [14], surgical trauma 
and physiological changes in the perioperative phase may 
negatively influence oncological outcome by promoting 
metastasis formation [15]. In particular, perioperative 
immunosuppression can lead to a metastasis-permissive 
state by hampering the main eliminator of circulating 
cancer cells, the cell-mediated immunity [16]. The perio-
perative phase represents a short but highly vulnerable 
phase of the overall disease course in cancer patients. 
Interference with its pro-metastatic aspects could thus 
positively affect long-term outcome. We sought to assess 
this effect by examining patients who continuously took 
aspirin before, during and after surgery and thus inhib-
ited the main partners in crime of CTCs: platelets.
Methods
Study population and propensity score matching
The institutional review board of the University of 
Munich (study #20-101) approved the study protocol. 
Patients undergoing pancreatic surgery at our institu-
tion between 01/2014 and 11/2016 were registered in a 
prospectively maintained database. The study period 
was chosen because in 2014 a change of the department 
head and standards in pancreatic surgery took place at 
our institution. We retrospectively identified patients 
for our study population from this database using a pre-
defined study protocol that was designed to address the 
research question. Inclusion criteria were: (1) confirmed 
diagnosis of pancreatic ductal adenocarcinoma (PDAC) 
by pathology, (2) exclusion of distant metastasis at time 
of surgery, (3) successful resection of primary tumor with 
curative intent, (4) postoperative survival and/or follow-
up of at least 12 weeks, (5) disease-free survival of at least 
6 weeks. Patients with diagnosis other than PDAC were 
excluded as well as patients that suffered from locally 
advanced disease that underwent neoadjuvant therapy. 
All PDAC in the database were staged and documented 
by a pathologist according to the 7th edition AJCC TNM 
criteria from 2010 [17]. Since we wanted to focus our 
analysis on the metastases that might be favored by the 
perioperative period, we excluded patients who devel-
oped metastases within the first 6 weeks after resection, 
as these must have presumably already existed at the time 
of surgery. We identified 18 patients who were already 
taking 100  mg aspirin daily at the time of in-patient 
admission for surgery as part of their regular medication 
for different indications and who were not paused for this 
medication at any time during their in-patient stay.
Variables
The following variables were extracted from the database 
as possible confounders: age, sex, American Society of 
Anesthesiologist (ASA) score, body mass index (BMI), 
preoperative serum level of carboanhydrate antigen 19-9 
(CA19-9), preoperative platelet count, type of resection, 
intraoperative blood transfusions received, necessity for 
vascular resection, TNM stage, maximum tumor diame-
ter, examined lymph nodes, lymph node ratio (number of 
positive nodes divided by resected nodes), residual tumor 
status (R0 wide, R0 narrow, R1; according to [18], tumor 
grading, perineural, vascular, and lymphovascular inva-
sion, and administration of adjuvant therapy.
Follow-up data was acquired by querying the Munich 
tumor register, by detailed analysis of the electronic 
patient files for most recent hospital visits and by con-
tacting patients by telephone.
Overall survival (OS) and disease-free survival (DFS) 
were determined as time interval between day of sur-
gery and day of death (OS)/last follow-up or diagnosis 
of recurrence (DFS)/last follow-up, respectively. Patients 
alive or recurrence-free, respectively, at last follow-up 
visit were censored in the analysis. Patients, in which 
death from disease was documented but no clear prior 
date of recurrence diagnosis could be determined, date 
of recurrence was set to the date of death for DFS. Since 
our hypothesis foresees an effect of perioperative aspirin 
specifically on hematogenous metastasis, we analyzed 
the time interval between surgery and first diagnosis of 
hematogenous metastasis as “hematogenous metastasis 
free survival (HMFS)”. Patients that died from other or 
unknown cause were censored at time of death from can-
cer specific survival analysis (DFS and HMFS). Patients 
that died with diagnosis of local recurrence or peritoneal 
carcinomatosis but without hematogenous metastasis 
were censored only in HMFS but not DFS.
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Propensity score matching
To reduce bias due to confounding variables, propen-
sity score matching (PSM) was performed. PS was esti-
mated as the predicted probability of a patient being 
on aspirin from a logistic regression model, consider-
ing variables that were available prior to surgery and 
potentially of prognostic value. PSM included T stage, 
age, sex, ASA score, and tumor diameter. We then 
formed matched pairs between the 18 patients from 
the aspirin group and the control group without aspi-
rin using a one-to-four greedy nearest neighbor match 
without replacement with a caliper width of 0.5 (maxi-
mum allowable difference in propensity scores) (SAS 
software, Cary, NC, USA). The logit of propensity score 
was used as distance metric and the effective caliper of 
the matching process was 0.176. Four control patients 
for each patient of the therapy group were not avail-
able under these matching conditions. Thus, the match-
ing process resulted in 18 patients in the therapy group 
matched to 64 in the control group (effectively 1:3.6 
ratio). Good variable balance achieved by the matching 
process was assured with a treated-to-control variance 
ratio of the logit of the propensity score of 1.44, which 
lies between 0.5 and 2 as proposed by Rubin [19]. Only 
patients matched with PS were included in the time-to-
event analyses.
Statistical methods
Propensity score matching was performed using SAS, all 
further analyses were conducted using SPSS© Statistics 
(version 20, IBM©). Continuous variables were expressed 
as median with interquartile range (IQR). To detect dif-
ferences in continuous variables, medians were com-
pared using Mann–Whitney-U test. Potential differences 
of confounders measured as categorical variables were 
assessed using cross tabulation and Fisher’s exact-testing. 
All univariate survival analyses were conducted using 
Kaplan–Meier estimates and groups compared with 
log-rank tests. Prior to survival analysis, continuously 
expressed confounders were categorized by dichotomiz-
ing at the median. Two-sided p-values below 0.05 were 
considered statistically significant. Median, 3- and 5-year 
survival rates were reported when available. In groups 
where the number of events was too low to calculate a 
median survival, mean survival was reported.
Confounding variables that showed influence on the 
survival estimates (OS, DFS, HMFS) with a p-value of 
≤ 0.10 were entered into a multivariate cox regression 
analysis from which hazard ratios, 95% confidence inter-
vals and two-sided p-values were reported. Parameters 
with missing data (e.g. adjuvant therapy) were included 
in the multivariate analysis by adding the category 
“unknown” to the respective variable to prevent listwise 
exclusion of cases from multivariate analysis.
Results
Baseline characteristics and tumor stage
Median age of patients was 71 years (IQR: 62–75) and the 
female to male ratio was 35%:65%. Sixty-seven percent of 
patients received a pancreaticoduodenectomy, followed 
by distal pancreatectomy in 22% of patients and total 
pancreatectomy in 11% of patients. As defined per study 
protocol and confirmed by histology, all patients suf-
fered from ductal adenocarcinoma of the pancreas. The 
predominant histopathological features were T3 tumor 
stage (93% of patients), poor differentiation (G3: 71% of 
patients) and presence of perineural invasion (Pn1: 87% 
of patients). Seventy-eight percent of patients showed 
clear resection margins after surgery (R0). Further patient 
characteristics are presented in Table 1.
Follow‑up data
Median follow up for all patients of this study was 
20.3 months (IQR: 12.2–31.2 months), with death occur-
ring in 51 patients (62.2%), tumor recurrence of any 
kind occurring in 64 patients (78%) and development of 
hematogenous metastasis in 50 patients (61%) during 
the follow-up period. Median overall survival, disease-
free survival, and hematogenous metastasis-free sur-
vival were 24.9 months (95% CI 19.0–30.7), 13.6 months 
(95% CI 10.9–16.3), and 18.3 months (95% CI 13.0–23.7). 
Three- and five-year survival rates for the whole study 
population were 34.7% and 23.5%. We were able to con-
firm routine administration of adjuvant chemotherapy 
in 59% of all patients with available data on the admin-
istration of chemotherapy. Reasons for the omission of 
chemotherapy were patient choice or poor performance 
status. In 32% of all patients, we were unable to obtain 
information on whether or not the recommended adju-
vant chemotherapy was administered.
Effect of aspirin on survival parameters
None of the baseline characteristics showed significant 
differences between groups except for the number of 
examined lymph nodes (Table  1). In patients with aspi-
rin intake, a median of 33 lymph nodes (IQR: 27–39) 
was resected and examined compared to a median of 
22 resected and examined lymph nodes (IQR: 19–34) in 
patients without aspirin intake (*p = 0.007). However, the 
number of examined lymph nodes did not show a sig-
nificant influence on any of the survival parameters (see 
Table 2).
Univariate analysis by Kaplan–Meier estimates and 
log-rank test showed that aspirin intake was associated 
with longer mean OS compared to no aspirin intake 
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(46.5 vs. 24.6  months, *p = 0.006), longer DFS (26.0 vs. 
10.5  months, *p = 0.001) and longer mean HMFS (41.9 
vs. 16.3 months, *p = 0.005) (Fig. 1, Table 2).
Other parameters that were significantly associated 
with longer OS were absent lymphovascular invasion 
(27.4 vs. 18.9  months, *p = 0.039), absent vascular inva-
sion (27.0 vs. 14.4  months, *p = 0.039) and administra-
tion of adjuvant chemotherapy (27.1 vs. 12.4  months, 
*p = 0.010). Another parameter that showed significant 
difference in median disease-free survival was absent 
vascular invasion (16.3 vs. 7.9  months, **p < 0.001). 
Parameters that were significantly associated with longer 
hematogenous metastasis free survival were tumor diam-
eter below median (27.0 vs. 16.2  months, *p = 0.032), 
absent lymphovascular invasion (26.0 vs. 13.9  months, 
*p = 0.049) and absent vascular invasion (24.9 vs. 
9.0 months, **p < 0.001) (Table 2).
All parameters with a p-value of 0.10 or below in uni-
variate analysis were subsequently tested in a multivari-
ate analysis using Cox regression (Table  3). Among all 
parameters, only aspirin intake was independently asso-
ciated with better OS (HR 0.36, *p = 0.023), DFS (HR 
0.32, **p = 0.001) and HMFS (HR 0.36, *p = 0.010).
Vascular invasion was independently associated with 
decreased overall survival (HR 3.01, **p = 0.001) and 
reduced hematogenous metastasis free survival (HR 4.80, 
**p < 0.001) (Table 3).
Table 1 Baseline characteristics for the study population
Parameter All (n = 82) No ASS (n = 64) ASS (n = 18) p
Agea 71.1 [62.1–75.1] 71.6 [62.1–76] 70.6 [64–72.1] 0.779
Sex 1.0
 Female 29 (35.4%) 23 (35.9%) 6 (33.3%)
 Male 53 (64.6%) 41 (64.1%) 12 (66.7%)
ASA score 0.09
 ASA II 16 (19.5%) 11 (17.2%) 5 (27.8%)
 ASA III 65 (79.3%) 53 (82.8%) 12 (66.7%)
 ASA IV 1 (1.2%) 0 (0%) 1 (5.6%)
BMI 24.2 [22.1–26] 24.3 [22.5–26.1] 23.2 [21.9–26] 0.398
Serum CA 19–9 (U/ml)a 88.4 [27–368] 96.7 [27.3–381.] 49.5 [13.5–339] 0.292
Platelet  counta (G/l) 232 [178–279] 235 [177–310] 225 [181–272] 0.760
Type of surgery 0.474
 PD 55 (67.1%) 45 (70.3%) 10 (55.6%)
 DP 18 (22%) 13 (20.3%) 5 (27.8%)
 TP 9 (11%) 6 (9.4%) 3 (16.7%)
RBC during surg. (units)a 0.404
 Yes 9 (11%) 6 (9.4%) 3 (16.7%)
 No 73 (89%) 58 (90.6%) 15 (83.3%)
Additional venous resection 0.778
 Yes 25 (30.5%) 19 (29.7%) 6 (33.3%)
 No 57 (69.5%) 45 (70.3%) 12 (66.7%)
Tumor diameter max (cm)a 3.3 [2.5–4.3] 3.2 [2.5–4.4] 3.3 [2.3–4.2] 0.771
T stage
 T1 + 2 6 (7.3%) 4 (6.2%) 2 (11.1%) 0.608
 T3 76 (92.7%) 60 (93.8%) 16(88.9%)
N stage 1.0
 N0 25 (30.5%) 20 (31.2%) 5 (27.8%)
 N1 57 (69.5%) 44 (68.8%) 13 (72.2%)
ELNa 26 [19–35] 25 [19–34] 33 [27–39] *0.007
LNRa 0.07 [0.0–0.16] 0.09 [0.0–0.17] 0.04 [0.0–0.08] 0.754
Grading
 G1 1 (1.2%) 1 (1.6%) 0 (0%)
 G2 23 (28%) 17 (26.6%) 6 (33.3%)
 G3 58 (70.7%) 46 (71.9%) 12 (66.7%)
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Table 1 (continued)
Differences in baseline characteristics were assessed by Fisher’s exact test for categorical and Mann–Whitney-U test for continuous variables
ASA American Society of Anesthesiologists Score, BMI body mass index, PD pancreaticoduodenectomy, DP distal pancreatectomy, total pancreatectomy, RBC packed 
red blood cells, ELN examined lymph nodes, LNR lymph node ratio
a Values expressed as median [interquartile range]
*p < 0.05
Parameter All (n = 82) No ASS (n = 64) ASS (n = 18) p
Perineural invasion 0.246
 Pn0 11 (13.4%) 7 (10.9%) 4 (22.2%)
 Pn1 71 (86.6%) 57 (89.1%) 14 (77.8%)
Vascular invasion 1.0
 V0 68 (82.9%) 53 (82.8%) 15 (83.3%)
 V1 14 (17.1%) 11 (17.2%) 3 (16.7%)
Lymphovascular invasion 0.282
 L0 49 (59.8%) 36 (56.2%) 13 (72.2%)
 L1 33 (40.2%) 28 (43.8%) 5 (27.8%)
R status 0.457
 R0 wide 29 (35.4%) 24 (37.5%) 5 (27.8%)
 R0 narrow 35 (42.7%) 25 (39.1%) 10 (55.6%)
 R1 18 (22%) 15 (23.4%) 3 (16.7%)
Adjuvant therapy 0.282
 Yes 48 (58.5%) 36 (56.2%) 12 (66.7%)
 No 8 (9.8%) 8 (12.5%) 0 (0%)
 Unknown 26 (31.7%) 20 (31.2%) 6 (33.3%)
Table 2 Results from univariate survival analyses of aspirin intake and confounders on overall (OS), disease-free (DFS), 
and hematogenous metastasis-free (HMFS) survival
Parameter Median  (meana) OS 
(95% CI) in months
3‑YSR 5‑YSR Log‑rank p Median  (meana) 
DFS (95% CI) 
in months
Log‑rank p Median  (meana) 
HMFS (95% CI) 
in months
Log‑rank p
Pt. on aspirin *0.006 *0.001 *0.005
 Yes 46.5a (35.6–57.4) 61.1% 61.1% 26.0 (16.7–35.3) 41.9a (30.3–53.4)
 No 24.6a (20.2–28.9) 26.3% n/a 10.5 (6.5–14.5) 16.3 (11.4–21.1)
Age 0.405 0.348 0.957
 ≤ Median 26.5 (16.3–36.8) 40.9% 26.2% 14.5 (8.2–20.8) 17.9 (12.1–23.8)
 > Median 24.9 (14.8–34.9) 27.4% n/a 13.5 (11.2–15.8) 21.5 (11.4–31.5)
Sex 0.555 0.856 0.949
 Female 24.2 (16.2–32.2) 29.2% n/a 13.9 (11.7–16.1) 18.3 (7.3–29.4)
 Male 27.1 (17.3–37.0) 36.7% 21.4% 13.5 (8.5–18.5) 19.7 (14.4–24.9)
BMI 0.127 0.601 0.956
 ≤ Median 35.0 (19.4–50.6) 47.9% 28.9% 13.5 (6.7–20.3) 19.6 (13.6–25.7)
 > Median 21.0 (17.3–24.6) 40.3% 24.3% 13.9 (10.5–17.3) 17.7 (7.3–28.1)
ASA score 0.702 0.754 0.596
 ASA II 26.5 (17.7–35.4) 26.7% n/a 14.5 (10.9–18.1) 14.5 (10.9–18.1)
 ASA III/IV 22.3 (14.4–30.2) 36.2% 21.2% 13.3 (9.7–16.9) 20.9 (12.7–29.0)
Platelet count 0.598 0.720 0.616
 Normal 24.2 (17.6–30.8) 34.0% n/a 13.6 (11.0–16.2) 17.9 (11.4–24.4)
 < 150 G/l 21.0 (9.8–32.2) n/a n/a 9.0 (7.8–10.2) 23.9a (14.8–32.9)
 > 400 G/l 37.8 (0–81.7) 66,7% n/a 19.7 (0.8–38.6) 19.7 (0.8–38.5)
Serum CA19-9 0.092 0.128 0.196
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BMI body mass index, ASA American Society of Anesthesiologists Score, PD pancreaticoduodenectomy, DP distal pancreatectomy, total pancreatectomy; ELN 
examined lymph nodes




Parameter Median  (meana) OS 
(95% CI) in months
3‑YSR 5‑YSR Log‑rank p Median  (meana) 
DFS (95% CI) 
in months
Log‑rank p Median  (meana) 
HMFS (95% CI) 
in months
Log‑rank p
 ≤ Median 29.1 (19.3–38.8) 41.8% n/a 15.5 (12.3–18.7) 26.0 (15.0–37.0)
 > Median 18.9 (11.3–26.5) 26.5% 21.2% 12.0 (7.0–17.0) 18.3 (10.7–25.9)
Type of resection 0.314 0.995 0.999
 PD 21.0 (17.7–24.2) 29.4% 21.5% 12.8 (9.3–16.3) 18.3 (9.2–27.4)
 DP 37.1 (21.6–52.6) 52.1% n/a 16.2 (14.7–17.7) 20.9 (14.4–27.3)
 TP 26.5 (22.4–30.7) 30.0% n/a 14.5 (7.3–21.7) 16.8 (12.1–21.4)
Tumor diameter 0.150 0.059 *0.032
 ≤ Median 27.0 (17.4–36.6) 41.7% 37.1% 13.9 (8.8–19.0) 27.0 (17.6–36.4)
 > Median 22.0 (13.4–30.6) 28.2% n/a 12.8 (7.0–18.6) 16.2 (12.9–19.4)
T-stage 0.352 0.249 0.402
 T1/2 37.8 (13.6–62.0) 60.0% 30.0% 16.7 (12.5–20.9) 19.7 (12.8–26.5)
 T3 24.2 (17.4–31.0) 32.8% n/a 13.3 (10.3–16.3) 17.9 (11.4–24.5)
Nodal stage 0.491 0.909 0.601
 N0 18.9 (13.9–23.9) 25.2% 25.2% 12.5 (9.1–15.9) 16.2 (8.1–24.2)
 N1 26.5 (21.2–31.8) 39.5% n/a 13.6 (10.4–16.8) 18.3 (11.8–24.8)
ELN 0.120 0.103 0.540
 ≤ Median 21.8 (15.7–27.9) 28.6% n/a 12.8 (9.0–16.6) 19.7 (14.3–25.0)
 > Median 27.1 (15.6–38.6) 40.6% 34.8% 14.9 (9.3–20.5) 17.7 (2.8–32.6)
Grading 0.840 0.713 0.240
 G1/2 35.0 (9.3–60.8) 41.0% n/a 16.2 (12.1–20.3) 27.2 (12.4–41.9)
 G3 24.2 (18.3–30.1) 32.9% 24.0% 12.5 (9.0–16.0) 17.7 (11.6–23.8)
Lymphovasc. invas *0.039 0.095 *0.049
 L0 27.4 (18.8–36.0) 42.1% 31.2% 16.3 (13.8–18.8) 26.0 (18.0–34.0)
 L1 18.9 (10.1–27.7) 24.6% n/a 9.0 (7.2–10.8) 13.9 (8.6–19.2)
Vascular invasion *0.039 **< 0.001 **< 0.001
 V0 27.0 (18.2–35.8) 38.7% 25.7% 16.3 (12.4–20.2) 24.9 (17.3–32.4)
 V1 14.4 (12.1–16.6) 16.3% n/a 7.9 (6.4–9.4) 9.0 (4.5–13.6)
Perineural invasion 0.424 0.153 0.216
 Pn0 35.0 (11.1–58.9) 40.4% 20.2% 27.8 (11.9–43.7) 32.7 (17.4–48.0)
 Pn1 24.2 (17.2–31.2) 33.6% n/a 13.3 (10.3–16.3) 17.7 (12.2–23.2)
R-status 0.366 0.756 0.225
 R0 wide 26.5 (18.3–34.8) 35.5% 24.3% 14.9 (11.2–18.6) 21.5 (11.4–31.5)
 R0 narrow 29.1 (15.8–42.3) 39.6% n/a 13.9 (9.6–18.2) 17.9 (9.6–26.3)
 R1 18.9 (6.0–31.8) 26.7% n/a 12.0 (4.6–19.4) 12.5 (1.2–23.7)
Add. venous resect 0.248 0.494 0.994
 Yes 17.6 (6.0–29.1) 25.0% n/a 12.5 (6.3–18.7) 18.3 (9.3–27.4)
 No 27.1 (19.0–35.2) 38.7% 22.7% 13.9 (11.6–16.2) 19.7 (12.7–26.6)
Adjuvant therapy 0.010 0.634 0.672
 Yes 27.1 (14.2–40.1) 43.1% n/a 15.5 (12.2–18.8) 19.7 (12.3–27.0)
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Discussion
Patients suffering from pancreatic cancer have a high 
risk for recurrence and death despite curative resection 
with the majority of patients succumbing to diffuse met-
astatic disease. In fact, 78% of the patients of our cura-
tively resected cohort developed a relapse in the follow-up 
period of our study and 60.6% died. Our survival results 
closely resemble those reported in the gemcitabine arm 
of ESPAC-4, which was the most recent multicentric ran-
domized controlled trial with adjuvant gemcitabine use at 
the time our patients were treated (OS: 25 vs. 25.5 months, 
DFS: 13.6 vs. 13.1 months) [20]. Most prognostically rele-
vant baseline characteristics were also comparable to those 
enrolled in ESPAC-4 [e.g. similar R0 rate (35.4% vs. 40%), 
maximum tumor diameter (33 mm vs. 30 mm), T3 stage 
(92.7% vs. 89%)]. Several of the confounders that influ-
enced survival in our study cohort have previously been 
described to do so in the literature [21, 22].
Aspects related to surgery, such as immunosuppres-
sion, release of tumor-supporting factors, and increase 
of circulating tumor cells (CTCs) by manipulation pre-
sumably favor the probability of distant metastases [15]. 
Platelets have been attributed important roles in increas-
ing the metastatic potential of CTCs by associating with 
them via tissue factor on the surface of cancer cells [23]. 
Not only does this screen cancer cells from natural killer 
cell-mediated killing, it also enables them to benefit from 
the bioactive molecules abundantly contained in and 
released by platelets (e.g. TGF-ß and PDGF) [23–25]. 
These molecules cause normal somatic cells, e.g. immune 
and endothelial cells, to act in favor for the metastatic 
process [4]. They also support the continuation of EMT 
pathway activation in CTCs, an important prerequi-
site for metastatic seeding and otherwise abrogated 
after losing contact with stromal signals in the primary 
tumor [26]. Thus, we speculated whether aspirin could 
Fig. 1 Overall, disease-free, and hematogenous metastasis-free survival in patients following curative pancreatic surgery with (red line) and without 
aspirin (blue line). Depicted is a overall survival, b disease-free survival, and c hematogenous metastasis free survival (HFMS) in months following 
pancreatic surgery. p-values were calculated by log-rank test
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counteract negative aspects of the surgical procedure 
and have a positive impact on patients in this vulnerable 
phase.
For many decades, aspirin was paused before surgery 
out of concern for excessive bleeding. This practice has 
changed only in recent years in our institution out of 
worry for increased cardiovascular events during surgery, 
especially owing to the temporarily increased activity of 
thromboxane A2 after discontinuation of aspirin ("aspi-
rin-withdrawal syndrome") [27]. While the decision to 
continue aspirin was not based on oncological reasons, 
it now allows us to assess the clinical outcomes in this 
patient cohort. In order to be able to detect an effect of 
perioperative aspirin at all, we considered it important to 
include only patients in the therapy group who took aspi-
rin permanently and without pausing.
Weighing up potential risks of aspirin, it is known to 
cause an increase in absolute risk for major bleeding in 
the general population from about 0.16% to 0.81% over a 
15-year period [28]. Most surgical studies, however, show 
no relevant increase in bleeding risk for patients on aspirin 
during the perioperative phase and demonstrate a generally 
high level of safety for the drug [29]. This is consistent with 
our observations, given that the rate of perioperative blood 
transfusions was evenly low in both groups of our study.
To our knowledge, there is no published data from 
randomized phase 3 studies that examine the efficacy 
of aspirin as cancer therapeutic for pancreatic cancer 
as an endpoint. However, there are manifold data from 
experimental, epidemiological, and observational studies, 
which support the hypothesis of an anti-cancer effect 
of aspirin [30]. In pre-clinical studies, aspirin has been 
shown to counteracts cancer stem cell features, desmo-
plasia and gemcitabine resistance, which was the adju-
vant chemotherapy used in in our patient cohort [31, 32]. 
Furthermore, aspirin reduced Foxp3+ regulatory T cells 
and prolonged survival in a mouse model and showed 
effects on Cox-2 expressed in cancer cells, which is 
involved in carcinogenic pathways (i.e. RAS and NF-κB) 
[33].
Metaanalyses of large cohort studies have linked regu-
lar aspirin intake with a reduced incidence of various 
cancers, including colorectal, gastric and prostate cancer 
[30]; while research into pancreatic cancer has yielded 
inconclusive results [34, 35]. Additionally, randomised 
controlled trials in cardiovascular disease suggest that 
aspirin may lead to a marked reduction in the mortality 
associated with several cancer entities. This may be due 
to a (50%) overall reduction in the occurence of metas-
tases. Further, in patients who primarily develop non-
metastatic adenocarcinoma, aspirin reducedthe risk of 
susequent metastasis formation by approximately 70% 
[10]. Patients from our study that continuously took 
aspirin showed significantly longer disease-free and 
hematogenous metastasis-free intervals (Table 3), which 
resulted in improved overall survival.
Due to the non-randomized nature and the small 
sample size of our study, it certainly does not prove 
that the observed survival benefit is in fact caused 
by aspirin use. Instead, if aspirin indeed proves to be 
Table 3 Results from multivariate cox regression of survival parameters
Parameter influencing overall survival HR 95% CI p
Pt. on aspirin (yes vs. no) 0.357 0.149–0.856 *0.021
Not included
 Vascular invasion (yes vs. no) 0.228
 Serum CA19-9 above median 0.490
 Lymphovascular invasion 0.440
 Adjuvant chemotherapy 0.061
Parameter influencing disease‑free survival
 Pt. on aspirin (yes vs. no) 0.316 0.158–0.634 **0.001
 Vascular invasion (yes vs. no) 3.008 1.541–5.871 **0.001
 Not included
  Tumor diameter (> median vs. ≤ median) 0.081
  Lymphovascular invasion 0.484
Parameter influencing hematogenous‑met‑free survival
 Pt. on aspirin (yes vs. no) 0.354 0.162–0.772 *0.009
 Vascular invasion (yes vs. no) 4.330 2.006–9.344 **< 0.001
  Not included
  Tumor diameter (> median vs. ≤ median) 0.065
  Lymphovascular invasion 0.258
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effective against pancreatic cancer, long-term adminis-
tration of aspirin could just as well explain the survival 
benefit observed in our study population by providing 
continuous protection against the formation of metas-
tases from CTCs prior to surgery or residual tumor 
cells after surgery. It is however plausible from the sus-
pected mechanism of action and cancer-favoring risks 
of the surgical procedure, that aspirin intake might be 
of particular importance in the perioperative setting. 
Only a prospective randomized controlled trial where 
patients in the therapy arm are started on aspirin as 
soon as the diagnosis of pancreatic cancer is suspected, 
and the medication is continued along with adjuvant 
chemotherapy until the end of the study could provide 
answers hereto. In some tumor entities (e.g. colorec-
tal carcinoma) aspirin may exert beneficial effects only 
after several years of administration, which may reflect 
the halting effect of aspirin on carcinogenesis, where-
ase recent studies could demonstrate that aspirin might 
also provide shortterm benefits by inhibition of metas-
tasis formation [10, 36, 37].
However, despite these broad indications for the effi-
cacy of aspirin in pancreatic cancer or even cancer in 
general and despite the drug being used safely for many 
decades in millions of patients, clinical data on the effi-
cacy against cancer is surprisingly sparse.
Conclusion
Our propensity score matched study demonstrates that 
patients undergoing curative resection of pancreatic 
adenocarcinoma with continuous perioperative aspirin 
intake show significantly better survival endpoints than 
patients without aspirin intake. Taken together with pre-
existing evidence, there is sufficient indication of efficacy 
to justify testing this hypothesis in a prospective rand-
omized study.
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